Adropin levels and target organ damage secondary to high blood pressure in the ED

Gülen, Bedia; Eken, Cenker; Kucukdagli, Okkes Taha; Serinken, Mustafa; Koçyiğit, Abdürrahim; Kılıç, Elif; Uyarel, Hüseyin

doi:10.1016/j.ajem.2016.04.014

Cited by 31 publications

(27 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, another study reported lower levels of adropin in adults with hypertension [42]. Low levels of adropin in hypertensive patients were also reported by Gulen et al [43]. Nevertheless, this work found that adropin levels in hypertensive patients do not correlate with acute hypertensive target organ damage [43].…”

Section: Adropin In the Cardiovascular Systemmentioning

confidence: 46%

“…Low levels of adropin in hypertensive patients were also reported by Gulen et al [43]. Nevertheless, this work found that adropin levels in hypertensive patients do not correlate with acute hypertensive target organ damage [43]. Similarly, low levels of adropin were also reported in pregnant women with hypertension [44].…”

Section: Adropin In the Cardiovascular Systemmentioning

confidence: 54%

See 1 more Smart Citation

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research

et al. 2020

View full text Add to dashboard Cite

Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene. Adropin is produced in the liver and brain, and also in peripheral tissues such as in the heart and gastrointestinal tract. Furthermore, adropin is present in the circulatory system. A decade after its discovery, there is evidence that adropin may contribute to body weight regulation, glucose and lipid homeostasis, and cardiovascular system functions. In this review, we summarize and discuss the physiological, metabolic, and pathophysiological factors regulating Enho as well as adropin. Furthermore, we review the literature addressing the role of adropin in adiposity and type 2 diabetes. Finally, we elaborate on the role of adropin in the context of the cardiovascular system, liver diseases, and cancer.

show abstract

Section: Adropin In the Cardiovascular Systemmentioning

confidence: 46%

Section: Adropin In the Cardiovascular Systemmentioning

confidence: 54%

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Adropin had a negative correlation with diastolic and systolic blood pressures and plasma endothelin 1 levels [ 31 ]. Whereas Çelik et al and Gulen et al reported that hypertensive patients had higher adropin levels compared with controls [ 32 , 33 ]. Chen M. et al reported that adropin is a novel regulator of blood pressure [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation

Sato

Yamashita

Shirai

et al. 2018

IJMS

101

View full text Add to dashboard Cite

Adropin, a peptide hormone expressed in liver and brain, is known to improve insulin resistance and endothelial dysfunction. Serum levels of adropin are negatively associated with the severity of coronary artery disease. However, it remains unknown whether adropin could modulate atherogenesis. We assessed the effects of adropin on inflammatory molecule expression and human THP1 monocyte adhesion in human umbilical vein endothelial cells (HUVECs), foam cell formation in THP1 monocyte-derived macrophages, and the migration and proliferation of human aortic smooth muscle cells (HASMCs) in vitro and atherogenesis in Apoe−/− mice in vivo. Adropin was expressed in THP1 monocytes, their derived macrophages, HASMCs, and HUVECs. Adropin suppressed tumor necrosis factor α-induced THP1 monocyte adhesion to HUVECs, which was associated with vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 downregulation in HUVECs. Adropin shifted the phenotype to anti-inflammatory M2 rather than pro-inflammatory M1 via peroxisome proliferator-activated receptor γ upregulation during monocyte differentiation into macrophages. Adropin had no significant effects on oxidized low-density lipoprotein-induced foam cell formation in macrophages. In HASMCs, adropin suppressed the migration and proliferation without inducing apoptosis via ERK1/2 and Bax downregulation and phosphoinositide 3-kinase/Akt/Bcl2 upregulation. Chronic administration of adropin to Apoe−/− mice attenuated the development of atherosclerotic lesions in the aorta, with reduced the intra-plaque monocyte/macrophage infiltration and smooth muscle cell content. Thus, adropin could serve as a novel therapeutic target in atherosclerosis and related diseases.

show abstract

“…However, adropin levels cannot be used as a marker of target organ damage (TOD) because of its similar levels in the groups with and without TOD. 16 There are also studies confirming an association between irisin and blood pressure. Irisin mediates energy homeostasis and it is produced by muscle cells, among others.…”

Section: Adropin Irisin and Hypertensionmentioning

confidence: 96%

Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease

Maciorkowska¹,

Musiałowska²,

Małyszko³

2019

Adv Clin Exp Med

View full text Add to dashboard Cite

Despite great advances in medicine, the proper treatment of arterial hypertension (AH), diabetes mellitus (DM) and chronic kidney disease (CKD) remains a major challenge. Untreated, undiagnosed AH or DM may lead to the development of CKD and consequently to the occurrence of cardiovascular events. Adropin and irisin are newly discovered proteins which may play a role in the development and progression of the chronic diseases mentioned above. Endothelium dysfunction could be a bonding point. The following review paper focuses on adropin and irisin concentrations and their correlations in AH, DM and CKD. Lower adropin concentrations have been measured in patients with primary AH when compared to healthy volunteers. Irisin has reduced blood pressure on nitric oxide (NO)-dependent pathways in experimental studies; a negative correlation between irisin and blood pressure values has also been observed in preeclamptic women. Irisin also plays a role in insulin sensitivity and metabolic disorders. Lower irisin levels have been observed in patients with DM type 2 in comparison to a nondiabetic control group. It is also lower in the serum of pregnant women with gestational DM. A negative correlation between irisin and estimated glomerular filtration rate (EGFR) has also been noted. Adropin and irisin are newly described myokines measured in human plasma in healthy and disease status. Their exact function has not been specified yet and requires further studies.

show abstract

Adropin levels and target organ damage secondary to high blood pressure in the ED

Cited by 31 publications

References 9 publications

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research

Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research

Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation

Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease

Contact Info

Product

Resources

About